Article Information
History
- December 21, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Juan Manuel Carreño1,
- Hala Alshammary1,
- Johnstone Tcheou1,
- Gagandeep Singh1,
- Ariel Raskin1,
- Hisaaki Kawabata1,
- Levy Sominsky1,
- Jordan Clark1,
- Daniel C. Adelsberg1,
- Dominika Bielak1,
- Ana Silvia Gonzalez-Reiche5,
- PSP/PARIS Study Group1,
- Komal Srivastava1,
- Emilia Mia Sordillo3,*,
- Goran Bajic1,*,
- Harm van Bakel5,*,
- Viviana Simon1,2,3,4,* and
- Florian Krammer1,3,*
- 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
- 2Division of Infectious Diseases, Department of Medicine, ISMMS
- 3Department of Pathology, Molecular and Cell based Medicine, ISMMS
- 4The Global Health and Emerging Pathogens Institute, ISMMS
- 5Department of Genetics and Genomic Sciences, ISMMS
- ↵*shared senior authorship, correspondence to emilia.sordillo{at}mountsinai.org, goran.bajic{at}mssm.edu, harm.vanbakel{at}mssm.edu, Viviana.simon{at}mssm.edu and florian.krammer{at}mssm.edu
Posted December 21, 2021.
Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
